$EIGR Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Eiger BioPharmaceuticals, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Eiger BioPharmaceuticals, Inc.. Get notifications about new insider transactions in Eiger BioPharmaceuticals, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 11 2021 | EIGR | Eiger BioPharmaceu ... | Ryali Sriram | Chief Financial Off ... | Option Exercise | A | 8.49 | 87,000 | 738,630 | 87,000 | |
| Apr 23 2021 | EIGR | Eiger BioPharmaceu ... | Sablich Kim | Director | Option Exercise | A | 8.43 | 25,000 | 210,750 | 25,000 | |
| Apr 12 2021 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Buy | P | 8.50 | 1,000 | 8,500 | 37,500 | 36.5 K to 37.5 K (+2.74 %) |
| Apr 12 2021 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Buy | P | 8.48 | 1,500 | 12,720 | 36,500 | 35 K to 36.5 K (+4.29 %) |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Option Exercise | A | 9.99 | 71,250 | 711,788 | 71,250 | |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Grant | A | 0.00 | 11,875 | 0 | 29,296 | 17.4 K to 29.3 K (+68.16 %) |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Sachdev Amit | Director | Option Exercise | A | 9.99 | 10,000 | 99,900 | 10,000 | |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Sachdev Amit | Director | Grant | A | 0.00 | 5,000 | 0 | 10,000 | 5 K to 10 K (+100.00 %) |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Ryali Sriram | Chief Financial Off ... | Option Exercise | A | 9.99 | 97,500 | 974,025 | 97,500 | |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Ryali Sriram | Chief Financial Off ... | Grant | A | 0.00 | 16,250 | 0 | 18,152 | 1.9 K to 18.2 K (+854.36 %) |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Patton Stephana Eilene | See Remarks | Option Exercise | A | 9.99 | 71,250 | 711,788 | 71,250 | |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Patton Stephana Eilene | See Remarks | Grant | A | 0.00 | 11,875 | 0 | 17,948 | 6.1 K to 17.9 K (+195.54 %) |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Murray Christine | Director | Option Exercise | A | 9.99 | 10,000 | 99,900 | 10,000 | |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Murray Christine | Director | Grant | A | 0.00 | 5,000 | 0 | 10,000 | 5 K to 10 K (+100.00 %) |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Ex VP & Chief Comme ... | Option Exercise | A | 9.99 | 71,250 | 711,788 | 71,250 | |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Ex VP & Chief Comme ... | Grant | A | 0.00 | 11,875 | 0 | 47,685 | 35.8 K to 47.7 K (+33.16 %) |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Loh Evan | Director | Option Exercise | A | 9.99 | 10,000 | 99,900 | 10,000 | |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Loh Evan | Director | Sell | S | 10.14 | 2,000 | 20,280 | 8,000 | 10 K to 8 K (-20.00 %) |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Loh Evan | Director | Grant | A | 0.00 | 5,000 | 0 | 10,000 | 5 K to 10 K (+100.00 %) |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Glenn Jeffrey S | Director | Option Exercise | A | 9.99 | 10,000 | 99,900 | 10,000 | |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Glenn Jeffrey S | Director | Grant | A | 0.00 | 5,000 | 0 | 76,355 | 71.4 K to 76.4 K (+7.01 %) |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Option Exercise | A | 9.99 | 20,000 | 199,800 | 20,000 | |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Grant | A | 0.00 | 5,000 | 0 | 35,000 | 30 K to 35 K (+16.67 %) |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Cory David A | President and CEO | Option Exercise | A | 9.99 | 281,000 | 2,807,190 | 281,000 | |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Cory David A | President and CEO | Grant | A | 0.00 | 47,000 | 0 | 117,846 | 70.8 K to 117.8 K (+66.34 %) |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Apelian David | Director | Option Exercise | A | 9.99 | 10,000 | 99,900 | 10,000 | |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Apelian David | Director | Grant | A | 0.00 | 5,000 | 0 | 10,000 | 5 K to 10 K (+100.00 %) |
| Jan 11 2021 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Ex VP & Chief Comme ... | Sell | S | 11.68 | 1,690 | 19,739 | 35,810 | 37.5 K to 35.8 K (-4.51 %) |
| Aug 12 2020 | EIGR | Eiger BioPharmaceu ... | Glenn Jeffrey S | Director | Buy | P | 11.44 | 4,500 | 51,465 | 5,000 | 500 to 5 K (+900.00 %) |
| Aug 12 2020 | EIGR | Eiger BioPharmaceu ... | Glenn Jeffrey S | Director | Buy | P | 11.28 | 500 | 5,638 | 500 | 0 to 500 |
| Aug 12 2020 | EIGR | Eiger BioPharmaceu ... | Glenn Jeffrey S | Director | Buy | P | 11.49 | 5,000 | 57,464 | 71,355 | 66.4 K to 71.4 K (+7.54 %) |
| Mar 17 2020 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Buy | P | 4.95 | 1,000 | 4,950 | 30,000 | 29 K to 30 K (+3.45 %) |
| Mar 17 2020 | EIGR | Eiger BioPharmaceu ... | Glenn Jeffrey S | Director | Buy | P | 5.03 | 30,000 | 150,813 | 66,355 | 36.4 K to 66.4 K (+82.52 %) |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Option Exercise | A | 5.60 | 50,000 | 280,000 | 50,000 | |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Grant | A | 7.31 | 1,500 | 10,965 | 15,921 | 14.4 K to 15.9 K (+10.40 %) |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Sachdev Amit | Director | Option Exercise | A | 5.60 | 10,000 | 56,000 | 10,000 | |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Sachdev Amit | Director | Grant | A | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Ryali Sriram | Chief Financial Off ... | Option Exercise | A | 5.60 | 65,000 | 364,000 | 65,000 | |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Ryali Sriram | Chief Financial Off ... | Grant | A | 7.31 | 229 | 1,674 | 1,628 | 1.4 K to 1.6 K (+16.37 %) |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Patton Stephana Eilene | See Remarks | Option Exercise | A | 5.60 | 65,000 | 364,000 | 65,000 | |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Patton Stephana Eilene | See Remarks | Grant | A | 7.31 | 820 | 5,994 | 4,820 | 4 K to 4.8 K (+20.50 %) |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Murray Christine | Director | Option Exercise | A | 5.60 | 10,000 | 56,000 | 10,000 | |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Murray Christine | Director | Grant | A | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Loh Evan | Director | Option Exercise | A | 5.60 | 10,000 | 56,000 | 10,000 | |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Loh Evan | Director | Grant | A | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Glenn Jeffrey S | Director | Option Exercise | A | 5.60 | 10,000 | 56,000 | 10,000 | |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Glenn Jeffrey S | Director | Grant | A | 0.00 | 5,000 | 0 | 36,355 | 31.4 K to 36.4 K (+15.95 %) |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Cory David A | President and CEO | Option Exercise | A | 5.60 | 230,000 | 1,288,000 | 230,000 | |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Cory David A | President and CEO | Grant | A | 7.31 | 1,500 | 10,965 | 69,346 | 67.8 K to 69.3 K (+2.21 %) |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Option Exercise | A | 5.60 | 20,000 | 112,000 | 20,000 | |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Grant | A | 0.00 | 5,000 | 0 | 29,000 | 24 K to 29 K (+20.83 %) |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Apelian David | Director | Option Exercise | A | 5.60 | 10,000 | 56,000 | 10,000 | |
| Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Apelian David | Director | Grant | A | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |
| Jan 31 2020 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Ex VP & Chief Comme ... | Option Exercise | A | 12.36 | 150,000 | 1,854,000 | 150,000 | |
| Jan 31 2020 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Ex VP & Chief Comme ... | Grant | A | 0.00 | 7,500 | 0 | 37,500 | 30 K to 37.5 K (+25.00 %) |
| Jan 30 2020 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Ex VP & Chief Comme ... | Buy | P | 13.52 | 5,000 | 67,603 | 30,000 | 25 K to 30 K (+20.00 %) |
| Jan 13 2020 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Buy | P | 13.94 | 4,000 | 55,760 | 24,000 | 20 K to 24 K (+20.00 %) |
| Sep 06 2019 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Grant | A | 7.95 | 1,500 | 11,921 | 14,421 | 12.9 K to 14.4 K (+11.61 %) |
| Sep 06 2019 | EIGR | Eiger BioPharmaceu ... | Ryali Sriram | Chief Financial Off ... | Grant | A | 9.37 | 149 | 1,396 | 1,399 | 1.3 K to 1.4 K (+11.92 %) |
| Sep 06 2019 | EIGR | Eiger BioPharmaceu ... | Cory David A | President and CEO | Grant | A | 7.95 | 1,500 | 11,921 | 67,846 | 66.3 K to 67.8 K (+2.26 %) |
| May 30 2019 | EIGR | Eiger BioPharmaceu ... | Sachdev Amit | Director | Option Exercise | A | 11.13 | 25,000 | 278,250 | 25,000 | |
| Apr 26 2019 | EIGR | Eiger BioPharmaceu ... | Cory David A | President and CEO | Buy | P | 11.26 | 343 | 3,862 | 66,346 | 66 K to 66.3 K (+0.52 %) |
| Apr 23 2019 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Buy | P | 11.10 | 5,000 | 55,495 | 20,000 | 15 K to 20 K (+33.33 %) |
| Apr 22 2019 | EIGR | Eiger BioPharmaceu ... | Ryali Sriram | Chief Financial Off ... | Buy | P | 11.08 | 1,250 | 13,853 | 1,250 | 0 to 1.3 K |
| Apr 22 2019 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Buy | P | 11.05 | 5,000 | 55,250 | 15,000 | 10 K to 15 K (+50.00 %) |
| Apr 22 2019 | EIGR | Eiger BioPharmaceu ... | Patton Stephana Eilene | See Remarks | Buy | P | 11.03 | 1,000 | 11,030 | 4,000 | 3 K to 4 K (+33.33 %) |
| Apr 22 2019 | EIGR | Eiger BioPharmaceu ... | Ryali Sriram | Chief Financial Off ... | Buy | P | 11.08 | 1,250 | 13,853 | 1,250 | 0 to 1.3 K |
| Apr 22 2019 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Buy | P | 11.05 | 5,000 | 55,250 | 15,000 | 10 K to 15 K (+50.00 %) |
| Apr 22 2019 | EIGR | Eiger BioPharmaceu ... | Patton Stephana Eilene | See Remarks | Buy | P | 11.03 | 1,000 | 11,030 | 4,000 | 3 K to 4 K (+33.33 %) |
| Mar 26 2019 | EIGR | Eiger BioPharmaceu ... | Apelian David | COO and Ex. Medical ... | Option Exercise | A | 14.31 | 110,500 | 1,581,255 | 110,500 | |
| Mar 26 2019 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Option Exercise | A | 14.31 | 50,000 | 715,500 | 50,000 | |
| Mar 26 2019 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Grant | A | 7.95 | 1,500 | 11,921 | 12,921 | 11.4 K to 12.9 K (+13.13 %) |
| Mar 26 2019 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Grant | A | 7.95 | 1,500 | 11,921 | 11,421 | 9.9 K to 11.4 K (+15.12 %) |
| Mar 26 2019 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Grant | A | 8.03 | 1,500 | 12,049 | 9,921 | 8.4 K to 9.9 K (+17.81 %) |
| Mar 26 2019 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Grant | A | 9.90 | 1,500 | 14,854 | 8,421 | 6.9 K to 8.4 K (+21.67 %) |
| Mar 26 2019 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Grant | A | 8.20 | 1,301 | 10,671 | 6,921 | 5.6 K to 6.9 K (+23.15 %) |
| Mar 26 2019 | EIGR | Eiger BioPharmaceu ... | Cory David A | President and CEO | Option Exercise | A | 14.31 | 200,000 | 2,862,000 | 200,000 | |
| Mar 26 2019 | EIGR | Eiger BioPharmaceu ... | Cory David A | President and CEO | Grant | A | 7.95 | 1,500 | 11,921 | 66,003 | 64.5 K to 66 K (+2.33 %) |
| Mar 26 2019 | EIGR | Eiger BioPharmaceu ... | Cory David A | President and CEO | Grant | A | 7.95 | 1,500 | 11,921 | 64,503 | 63 K to 64.5 K (+2.38 %) |
| Mar 26 2019 | EIGR | Eiger BioPharmaceu ... | Cory David A | President and CEO | Grant | A | 8.03 | 1,500 | 12,049 | 63,003 | 61.5 K to 63 K (+2.44 %) |
| Mar 26 2019 | EIGR | Eiger BioPharmaceu ... | Cory David A | President and CEO | Grant | A | 9.90 | 1,500 | 14,854 | 61,503 | 60 K to 61.5 K (+2.50 %) |
| Mar 26 2019 | EIGR | Eiger BioPharmaceu ... | Cory David A | President and CEO | Grant | A | 8.20 | 1,325 | 10,868 | 60,003 | 58.7 K to 60 K (+2.26 %) |
| Mar 26 2019 | EIGR | Eiger BioPharmaceu ... | Murray Christine | Director | Option Exercise | A | 13.41 | 10,000 | 134,100 | 10,000 | |
| Mar 25 2019 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Option Exercise | A | 13.41 | 10,000 | 134,100 | 10,000 | |
| Mar 25 2019 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Option Exercise | A | 13.41 | 10,000 | 134,100 | 10,000 | |
| Mar 25 2019 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Option Exercise | A | 13.41 | 20,000 | 268,200 | 20,000 | |
| Mar 25 2019 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Option Exercise | A | 13.41 | 20,000 | 268,200 | 20,000 | |
| Mar 25 2019 | EIGR | Eiger BioPharmaceu ... | Glenn Jeffrey S | Director | Option Exercise | A | 14.31 | 10,000 | 143,100 | 10,000 | |
| Mar 25 2019 | EIGR | Eiger BioPharmaceu ... | Glenn Jeffrey S | Director | Option Exercise | A | 14.31 | 10,000 | 143,100 | 10,000 | |
| Mar 25 2019 | EIGR | Eiger BioPharmaceu ... | Loh Evan | Director | Option Exercise | A | 14.31 | 10,000 | 143,100 | 10,000 | |
| Mar 25 2019 | EIGR | Eiger BioPharmaceu ... | Loh Evan | Director | Option Exercise | A | 14.31 | 10,000 | 143,100 | 10,000 | |
| Mar 25 2019 | EIGR | Eiger BioPharmaceu ... | Patton Stephana Eilene | See Remarks | Option Exercise | A | 14.31 | 90,000 | 1,287,900 | 90,000 | |
| Mar 25 2019 | EIGR | Eiger BioPharmaceu ... | Patton Stephana Eilene | See Remarks | Option Exercise | A | 14.31 | 90,000 | 1,287,900 | 90,000 | |
| Feb 06 2019 | EIGR | Eiger BioPharmaceu ... | Cory David A | President and CEO | Buy | P | 14.13 | 227 | 3,208 | 58,678 | 58.5 K to 58.7 K (+0.39 %) |
| Jan 09 2019 | EIGR | Eiger BioPharmaceu ... | Murray Christine | Director | Option Exercise | A | 12.00 | 25,000 | 300,000 | 25,000 | |
| Jan 04 2019 | EIGR | Eiger BioPharmaceu ... | Ryali Sriram | Chief Financial Off ... | Option Exercise | A | 10.46 | 90,000 | 941,400 | 90,000 | |
| Dec 20 2018 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Buy | P | 9.98 | 5,000 | 49,900 | 10,000 | 5 K to 10 K (+100.00 %) |
| Dec 10 2018 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Buy | P | 11.26 | 5,000 | 56,300 | 5,000 | 0 to 5 K |
| Nov 30 2018 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Buy | P | 10.21 | 4,000 | 40,840 | 25,000 | 21 K to 25 K (+19.05 %) |
| Nov 28 2018 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Buy | P | 10.07 | 6,000 | 60,447 | 21,000 | 15 K to 21 K (+40.00 %) |
| Nov 28 2018 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Buy | P | 10.07 | 6,000 | 60,447 | 21,000 | 15 K to 21 K (+40.00 %) |
| Nov 28 2018 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Buy | P | 9.92 | 7,500 | 74,408 | 15,000 | 7.5 K to 15 K (+100.00 %) |
| Nov 28 2018 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Buy | P | 9.92 | 7,500 | 74,408 | 15,000 | 7.5 K to 15 K (+100.00 %) |
| Nov 28 2018 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Buy | P | 9.75 | 7,500 | 73,143 | 7,500 | 0 to 7.5 K |
| Nov 28 2018 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Buy | P | 9.75 | 7,500 | 73,143 | 7,500 | 0 to 7.5 K |
| Oct 22 2018 | EIGR | Eiger BioPharmaceu ... | INTERWEST PARTNERS X LP | 10% Owner | Sell | S | 12.00 | 26,465 | 317,606 | 1,362,327 | 1.4 M to 1.4 M (-1.91 %) |
| Oct 22 2018 | EIGR | Eiger BioPharmaceu ... | INTERWEST PARTNERS X LP | 10% Owner | Sell | S | 12.07 | 210,800 | 2,544,714 | 1,388,792 | 1.6 M to 1.4 M (-13.18 %) |
| Apr 04 2018 | EIGR | Eiger BioPharmaceu ... | Quan Joanne | Chief Medical Offic ... | Option Exercise | M | 2.06 | 4,000 | 8,240 | 22,256 | |
| Apr 04 2018 | EIGR | Eiger BioPharmaceu ... | Quan Joanne | Chief Medical Offic ... | Sell | S | 10.00 | 4,000 | 40,000 | 0 | 4 K to 0 (-100.00 %) |
| Apr 04 2018 | EIGR | Eiger BioPharmaceu ... | Quan Joanne | Chief Medical Offic ... | Buy | M | 2.06 | 4,000 | 8,240 | 4,000 | 0 to 4 K |
| Mar 16 2018 | EIGR | Eiger BioPharmaceu ... | Glenn Jeffrey S | Director | Option Exercise | A | 9.50 | 10,000 | 95,000 | 10,000 | |
| Mar 16 2018 | EIGR | Eiger BioPharmaceu ... | Loh Evan | Director | Option Exercise | A | 9.50 | 10,000 | 95,000 | 10,000 | |
| Mar 16 2018 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Option Exercise | A | 9.50 | 10,000 | 95,000 | 10,000 | |
| Mar 16 2018 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Option Exercise | A | 9.50 | 10,000 | 95,000 | 10,000 | |
| Mar 16 2018 | EIGR | Eiger BioPharmaceu ... | Apelian David | COO and Ex. Medical ... | Option Exercise | A | 9.50 | 37,000 | 351,500 | 37,000 | |
| Mar 16 2018 | EIGR | Eiger BioPharmaceu ... | Cory David A | President and CEO | Option Exercise | A | 9.50 | 190,000 | 1,805,000 | 190,000 | |
| Mar 16 2018 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Option Exercise | A | 9.50 | 60,000 | 570,000 | 60,000 | |
| Mar 16 2018 | EIGR | Eiger BioPharmaceu ... | Quan Joanne | Chief Medical Offic ... | Option Exercise | A | 9.50 | 60,000 | 570,000 | 60,000 | |
| Mar 16 2018 | EIGR | Eiger BioPharmaceu ... | WELCH JAMES H | Chief Financial Off ... | Option Exercise | A | 9.50 | 60,000 | 570,000 | 60,000 | |
| Jan 09 2018 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Option Exercise | A | 13.70 | 25,000 | 342,500 | 25,000 | |
| Jan 09 2018 | EIGR | Eiger BioPharmaceu ... | Apelian David | COO and Ex. Medical ... | Option Exercise | A | 13.70 | 150,000 | 2,055,000 | 150,000 | |
| Oct 06 2017 | EIGR | Eiger BioPharmaceu ... | Apelian David | Director | Option Exercise | A | 10.75 | 25,000 | 268,750 | 25,000 | |
| Sep 18 2017 | EIGR | Eiger BioPharmaceu ... | Loh Evan | Director | Option Exercise | A | 11.15 | 25,000 | 278,750 | 25,000 | |
| Sep 05 2017 | EIGR | Eiger BioPharmaceu ... | Glenn Jeffrey S | Director | Buy | P | 9.53 | 15,000 | 142,950 | 31,355 | 16.4 K to 31.4 K (+91.72 %) |
| Apr 14 2017 | EIGR | Eiger BioPharmaceu ... | Kjellson Nina S | Director | Option Exercise | A | 8.50 | 10,000 | 85,000 | 10,000 | |
| Apr 13 2017 | EIGR | Eiger BioPharmaceu ... | Bramlage Charles | Director | Option Exercise | A | 8.50 | 10,000 | 85,000 | 10,000 | |
| Apr 13 2017 | EIGR | Eiger BioPharmaceu ... | ENGLEMAN EDGAR | Director | Option Exercise | A | 8.50 | 10,000 | 85,000 | 10,000 | |
| Apr 13 2017 | EIGR | Eiger BioPharmaceu ... | Glenn Jeffrey S | Director | Option Exercise | A | 8.50 | 10,000 | 85,000 | 10,000 | |
| Apr 13 2017 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Option Exercise | A | 8.50 | 10,000 | 85,000 | 10,000 | |
| Mar 14 2017 | EIGR | Eiger BioPharmaceu ... | Quan Joanne | Chief Medical Offic ... | Option Exercise | A | 11.75 | 30,000 | 352,500 | 30,000 | |
| Mar 14 2017 | EIGR | Eiger BioPharmaceu ... | Martins Eduardo Bruno | SVP, Liver and Infe ... | Option Exercise | A | 11.75 | 30,000 | 352,500 | 30,000 | |
| Mar 14 2017 | EIGR | Eiger BioPharmaceu ... | Cory David A | President and CEO | Option Exercise | A | 11.75 | 133,000 | 1,562,750 | 133,000 | |
| Mar 14 2017 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Option Exercise | A | 11.75 | 40,000 | 470,000 | 40,000 | |
| Mar 14 2017 | EIGR | Eiger BioPharmaceu ... | WELCH JAMES H | Chief Financial Off ... | Option Exercise | A | 11.75 | 40,000 | 470,000 | 40,000 | |
| Nov 21 2016 | EIGR | Eiger BioPharmaceu ... | Glenn Jeffrey S | Director | Buy | P | 12.90 | 460 | 5,934 | 460 | 0 to 460 |
| Nov 21 2016 | EIGR | Eiger BioPharmaceu ... | Glenn Jeffrey S | Director | Buy | P | 12.73 | 15,000 | 190,950 | 16,355 | 1.4 K to 16.4 K (+1,107.01 %) |
| Aug 22 2016 | EIGR | Eiger BioPharmaceu ... | Vivo Ventures VI, LLC | 10% Owner | Buy | P | 16.00 | 1,364 | 21,824 | 12,996 | 11.6 K to 13 K (+11.73 %) |
| Aug 22 2016 | EIGR | Eiger BioPharmaceu ... | Vivo Ventures VI, LLC | 10% Owner | Buy | P | 16.00 | 186,136 | 2,978,176 | 1,774,096 | 1.6 M to 1.8 M (+11.72 %) |
| Aug 19 2016 | EIGR | Eiger BioPharmaceu ... | Cory David A | President and CEO | Buy | P | 15.70 | 1,562 | 24,523 | 58,451 | 56.9 K to 58.5 K (+2.75 %) |
| Aug 19 2016 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Buy | P | 15.70 | 3,125 | 49,063 | 5,620 | 2.5 K to 5.6 K (+125.25 %) |
| Jun 22 2016 | EIGR | Eiger BioPharmaceu ... | WELCH JAMES H | Chief Financial Off ... | Buy | P | 19.79 | 500 | 9,897 | 2,500 | 2 K to 2.5 K (+25.00 %) |
| Jun 22 2016 | EIGR | Eiger BioPharmaceu ... | WELCH JAMES H | Chief Financial Off ... | Buy | P | 19.80 | 2,000 | 39,592 | 2,000 | 0 to 2 K |
| Jun 14 2016 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Buy | P | 22.20 | 420 | 9,324 | 2,495 | 2.1 K to 2.5 K (+20.24 %) |
| Jun 14 2016 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Buy | P | 22.17 | 100 | 2,217 | 2,075 | 2 K to 2.1 K (+5.06 %) |
| Jun 14 2016 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Buy | P | 22.16 | 730 | 16,177 | 1,975 | 1.2 K to 2 K (+58.63 %) |
| May 23 2016 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Buy | P | 19.99 | 745 | 14,893 | 1,245 | 500 to 1.2 K (+149.00 %) |
| May 23 2016 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Buy | P | 19.52 | 500 | 9,760 | 500 | 0 to 500 |
| Apr 04 2016 | EIGR | Eiger BioPharmaceu ... | ENGLEMAN EDGAR | Director | Option Exercise | A | 15.75 | 25,000 | 393,750 | 25,000 | |
| Apr 01 2016 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Option Exercise | A | 15.75 | 23,000 | 362,250 | 23,000 | |
| Apr 01 2016 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Option Exercise | A | 15.75 | 25,000 | 393,750 | 25,000 |